Work Here?
Johnson & Johnson
Work Here?
Global healthcare company offering pharma, devices.
Johnson & Johnson
Work Here?
Global healthcare company offering pharma, devices.
Overview
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
About Johnson & Johnson
Industries
Healthcare
Consumer Goods
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion; guidance reached $101.1 billion.
- Tremfya jumped 72.5% to $2 billion in Q2 2026, replacing lost Stelara revenue.
- MONARCH QUEST 3 cleared FDA on August 17, 2026, strengthening lung-cancer robotics adoption.
What critics are saying
- Stelara fell 55.7% in Q2 2026; biosimilars keep pressuring immunology through 2027.
- The July 27, 2026 talc deal commits $5.5 billion and prolongs legal uncertainty.
- MedTech trails Intuitive Surgical and Medtronic; OTTAVA faces commercialization delays and share loss.
What makes Johnson & Johnson unique
- J&J spans pharma and MedTech, reducing dependence on any single patent cycle.
- Tremfya, Darzalex, and Inlexzo drive 2026 growth after Stelara's decline.
- MONARCH QUEST 3 and OTTAVA extend J&J into AI-guided robotics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Stock Price
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.
Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.
Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.
Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.
Johnson & Johnson received FDA clearance for its MONARCH QUEST 3 bronchoscopy system, a software update introducing AI-powered tools for procedure planning and lung nodule segmentation to its robotic-assisted bronchoscopy platform. The clearance expands Johnson & Johnson's capabilities in minimally invasive diagnostics and treatment within its MedTech portfolio. New digital ecosystem features are designed to support broader adoption of robotic and AI-guided tools in hospital and clinical settings. The launch forms part of Johnson & Johnson's strategy to expand MedTech and robotic surgery as larger earnings drivers alongside its pharmaceutical business. The system enters a competitive market where Intuitive Surgical and Medtronic already operate in AI-guided surgical procedures.
Johnson & Johnson is Hiring for 907 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Johnson & Johnson
Industries
Healthcare
Consumer Goods
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Johnson & Johnson is Hiring for 907 Jobs on Simplify!
Find jobs on Simplify and start your career today